Prescriber Scope of Practice for Anxiety in Michigan

If you’re a psychiatrist or PMHNP treating anxiety disorders, you’re navigating one of the most complex regulatory landscapes in telehealth right now. Between DEA extensions, state-by-state prescribing rules, and the reality that many effective anxiety medications are controlled substances, staying compliant while delivering quality care requires understanding both federal and state regulations.

Here’s what you need to know to practice legally and confidently — whether you’re treating generalized anxiety disorder, panic disorder, or social anxiety through telehealth or in-person care.

The Federal Baseline: DEA Telehealth Rules for Controlled Substances

The biggest question for anxiety providers: Can I prescribe benzodiazepines via telehealth without seeing the patient in person first?

As of early 2025, the answer is yes — but it’s temporary.

The DEA has extended COVID-era telehealth prescribing flexibilities through December 31, 2025. This means you can prescribe Schedule II–V controlled substances (including benzodiazepines like alprazolam, clonazepam, and lorazepam) via telemedicine without an initial in-person exam, as long as you:

• Conduct an appropriate evaluation via live audiovisual telehealth
• Have a valid DEA registration
• Comply with state laws and documentation requirements
• Meet standard-of-care expectations

This flexibility has been critical for anxiety treatment access. Before COVID, the Ryan Haight Act required an in-person medical evaluation before prescribing any controlled substance ‘by means of the Internet.’ That meant starting a patient on Xanax for panic disorder required at least one office visit — a barrier that kept many anxious patients from getting help.

But here’s the catch: This is the third temporary extension. In 2023, the DEA proposed new rules that would have reinstated the in-person visit requirement (with limited exceptions), sparking over 38,000 public comments from providers and patients. The DEA backed off and is now working on a ‘new path forward for telemedicine,’ but we don’t know what that will look like or when it will take effect.

What this means for your practice: Enjoy the current flexibility, but prepare for potential changes. Some strategies providers are considering:

• Building hybrid care models with affiliate clinics for in-person visits if needed
• Documenting telehealth exams thoroughly to demonstrate standard-of-care compliance
• Staying current on DEA announcements (they’ve promised guidance in 2025)
• Considering the special telemedicine DEA registration if/when it becomes available

For non-controlled anxiety medications (SSRIs, SNRIs, buspirone, hydroxyzine), none of these federal restrictions apply — you can prescribe them via telehealth following standard practice guidelines.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Psychiatrists vs. PMHNPs: Different Scopes, Different Rules

Psychiatrists: Full Authority, Full Compliance Burden

As a psychiatrist, your scope of practice is the broadest in mental health care. You have full independent practice authority in every state — no supervision or collaboration agreements required. You can:

• Diagnose any anxiety or related disorder
• Prescribe any medication, from SSRIs to Schedule II controlled substances
• Provide psychotherapy (though many psychiatrists focus on medication management)
• Practice autonomously via telehealth across state lines (with proper licensure)

The regulatory challenges for psychiatrists aren’t about scope limitations — they’re about compliance with prescribing regulations:

Multi-State Licensing: You must be licensed in every state where your patients are located. California and New York aren’t in the Interstate Medical Licensure Compact (IMLC), so you’ll need to go through their full licensing processes. Texas, Illinois, Pennsylvania, and Florida are IMLC states, which can streamline the process if you already hold an IMLC license.

Prescription Drug Monitoring Program (PDMP) Checks: Nearly every state mandates PDMP checks before prescribing controlled substances. For example:

• New York requires checking the I-STOP registry before every Schedule II–IV prescription
• Florida requires PDMP checks before prescribing any controlled substance and every 90 days for ongoing therapy
• Pennsylvania requires checking before each benzodiazepine or opioid prescription
• California requires PDMP checks at least every 4 months for Schedule II–IV drugs

Integrate these checks into your workflow — state boards audit for compliance, and it’s both a legal requirement and patient safety measure.

E-Prescribing Requirements: Most states now require or strongly encourage electronic prescribing of controlled substances. California and New York mandate e-prescriptions for all medications. You’ll need DEA-compliant EPCS (Electronic Prescribing of Controlled Substances) software with two-factor authentication.

State Controlled Substance Licenses: Some states (like Illinois and Florida) require a separate state controlled substance license in addition to your DEA registration.

PMHNPs: Expertise Meets State-by-State Variation

Psychiatric Mental Health Nurse Practitioners can diagnose and treat anxiety disorders in all states, but the level of independence and prescribing authority varies dramatically by state.

Practice Authority Breakdown:

Full or Near-Full Practice States (for experienced PMHNPs):

• New York: Full practice after 3,600 hours of experience (no physician collaboration needed)
• Illinois: Full practice authority available after 4,000 hours and additional training
• California: Transitioning — limited independence in certain settings as of 2023; full independence across all settings by 2026 (AB 890)

Restricted Practice States (physician collaboration required):

• Texas: Must have a Prescriptive Authority Agreement with a physician; physician can supervise maximum 7 NPs
• Florida: Requires supervisory protocol with a physician (psychiatric NPs not included in Florida’s autonomous NP category)
• Pennsylvania: Collaborative agreement required; physician can supervise up to 4 NPs

Controlled Substance Prescribing — Where It Gets Complicated:

Even with prescriptive authority, PMHNPs face state-specific limits on controlled substances:

Texas: APRNs cannot prescribe Schedule II controlled substances in outpatient settings except in hospitals or hospice care. For anxiety treatment, this mainly affects comorbid ADHD patients (you can’t prescribe stimulants). Most anxiety medications (benzodiazepines are Schedule IV) are allowed.

Florida: NPs can only prescribe Schedule II for up to 7 days unless they’re a certified psychiatric nurse treating mental illness — then the 7-day limit doesn’t apply. This carve-out recognizes psychiatric specialists’ need for flexibility.

Pennsylvania: NPs can prescribe Schedule II for up to 30 days and Schedule III–IV for up to 90 days, under their collaborative agreement. For benzodiazepines (Schedule IV), this means 90-day prescriptions are allowed.

Illinois: NPs with full practice authority can prescribe Schedule II–V independently, but must have a consultation relationship with a physician for the first 5 years when prescribing Schedule II opioids. For benzodiazepines and other Schedule III–V drugs, no physician consultation required.

California: NPs can prescribe controlled substances under standardized procedures (currently) or independently under the new license categories (as of 2023–2026 transition).

New York: NPs can prescribe Schedule II–V with DEA registration; experienced NPs do so independently after meeting the 3,600-hour threshold.

State-Specific Telehealth Prescribing Rules

Beyond practice authority, each state has its own telehealth and prescribing requirements:

California

• No in-person exam required by state law if standard of care is met via telehealth
• Telehealth exam (even asynchronous components) acceptable for prescribing
• E-prescribing required for all medications (as of 2022)
• Must check CURES PDMP for Schedule II–IV at least every 4 months
• Not in IMLC — need full California license to practice there

Texas

• Must establish care via synchronous audiovisual exam for new patients
• Teleprescribing controlled substances allowed except for chronic pain management (doesn’t affect anxiety treatment)
• Mandatory PDMP check for opioids, benzodiazepines, barbiturates, and carisoprodol
• IMLC member state (easier multi-state licensing for physicians)
• APRNs cannot prescribe Schedule II outside hospital/hospice settings

Florida

• Explicit patient consent required for telehealth treatment
• Schedule II via telehealth banned except for psychiatric treatment, inpatient, hospice, or nursing home care (psychiatric exception is key for mental health providers)
• PDMP (E-FORCSE) check required before each controlled substance prescription and every 90 days
• Out-of-state telehealth provider registration available (can practice to FL patients without full FL license if you qualify)
• E-prescribing mandated for controlled substances

New York

• Telehealth permitted for evaluations — no state-mandated in-person exam
• I-STOP/PDMP check mandatory before every Schedule II–IV prescription
• E-prescribing required for all medications (since 2016)
• Experienced NPs (3,600+ hours) can practice independently
• Not in IMLC — full NY license required

Pennsylvania

• Telehealth allowed if standard of care met (real-time audiovisual recommended for initial exams)
• PDMP check required before initial benzodiazepine or opioid prescription and for each subsequent refill
• E-prescribing mandatory for controlled substances (Act 96, since 2019)
• NPs require collaborative agreement with physician
• IMLC member state

Illinois

• No in-person exam requirement — standard of care determines appropriateness
• Audio-only telehealth permitted for mental health services when video unavailable
• PDMP registration and consultation required for Schedule II prescriptions
• State controlled substance license required in addition to DEA registration
• NPs with full practice authority can prescribe independently (after 4,000 hours)
• IMLC member state

Common Compliance Pitfalls to Avoid

Don’t skip the PDMP check. This is the #1 audit target. Every state tracks this, and failure to check can result in board discipline. Integrate it into your EHR workflow so it’s automatic.

Don’t use telephone-only for new controlled substance prescriptions. While some states allow audio-only telehealth for mental health, federal DEA rules currently require at least audiovisual for new controlled prescriptions (with limited exceptions). Use video for initial evaluations.

Don’t assume your home state rules apply everywhere. If you’re practicing in multiple states, each state’s regulations govern care for patients in that state. A PMHNP who can prescribe independently in Illinois still needs physician collaboration for Texas patients.

Don’t ignore documentation requirements. Telehealth visits must be documented just like in-person visits. Some states (Florida, Illinois) require documented patient consent for telehealth treatment.

Don’t practice without proper licensure. Treating a patient located in a state where you’re not licensed — even via telehealth — is practicing medicine without a license. This is a serious violation with severe penalties.

The Economics: Why Platform Models Make Sense

Here’s the reality of DIY patient acquisition for a psychiatric practice:

Traditional marketing costs add up fast:

• SEO: 6–12 months of investment ($2,000–5,000/month) before meaningful results
• Google Ads: $15–40+ per click for mental health keywords; realistic cost per booked patient is $200–400+
• Directory listings (Psychology Today, Zocdoc): Monthly fees plus per-booking charges; you compete with hundreds of other providers
• Total monthly marketing spend for a growing practice: $3,000–5,000+ with uncertain ROI

When you factor in:

• Agency/consultant fees for marketing expertise
• Staff time to handle and qualify leads
• No-show rates from cold leads
• Testing and optimization periods
• Failed campaigns and wasted ad spend

…the true cost per acquired psychiatric patient through DIY marketing is typically $200–500+ when you account for everything.

The platform model flips this: Instead of gambling $3,000–5,000/month on marketing that might not work, you pay only when a qualified patient books with you. Klarity Health uses a pay-per-appointment model — no upfront marketing spend, no monthly subscriptions, just a standard listing fee per new patient lead.

What you get:

• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• Multi-state licensing support and compliance infrastructure
• You control your schedule — only pay when you see patients

That’s guaranteed ROI instead of uncertain marketing experiments. For most providers — especially those starting out or scaling — this removes the risk entirely while letting you focus on clinical care instead of marketing campaigns.

What’s Next: Preparing for Regulatory Changes

The telehealth prescribing landscape is in flux. Here’s how to prepare:

Stay informed on DEA rules. The agency has promised new telemedicine regulations in 2025. Sign up for DEA email updates and join professional associations (APA, AANP) that track regulatory changes.

Build flexibility into your practice model. If in-person visits become required for controlled substances, have a plan: hybrid care with partner clinics, limiting controlled prescriptions to established patients, or focusing on non-controlled anxiety treatments (CBT-focused medication management with SSRIs/SNRIs).

Document everything. Thorough documentation of your telehealth exams — including why the modality was appropriate, what you observed, and how you established rapport and assessed mental status — will be critical if regulations tighten or if your care is ever reviewed.

Consider multi-state licensing strategically. If you’re joining a telehealth platform, prioritize states with strong regulatory environments for your provider type. For psychiatrists, all states work. For PMHNPs, focus on full-practice states if you value autonomy.

Join a platform with compliance infrastructure. Managing state-by-state variations in PDMP requirements, e-prescribing, collaborative agreements (for NPs), and licensing is complex. Platforms like Klarity Health handle this backend compliance work, ensuring you’re always practicing within state regulations.

Ready to Join a Telehealth Platform That Handles the Complexity?

Anxiety is the most common mental health condition in America, and demand for psychiatric prescribers has never been higher. But navigating 50 different state regulatory systems, federal DEA rules, and the economics of patient acquisition shouldn’t be what keeps you from serving more patients.

Klarity Health provides the infrastructure: pre-qualified patients, built-in telehealth technology, multi-state compliance support, and a pay-per-appointment model that eliminates marketing risk. You provide the clinical expertise.

Explore joining Klarity’s provider network and start treating anxiety patients in your licensed states — without the headache of marketing, compliance management, or wondering where your next patient will come from.

Frequently Asked Questions

Can I prescribe benzodiazepines via telehealth in 2025?

Yes, under current DEA temporary rules (extended through December 31, 2025), you can prescribe Schedule IV benzodiazepines via telehealth after conducting an appropriate audiovisual evaluation, even for new patients. However, you must also comply with your state’s telehealth and prescribing laws (PDMP checks, e-prescribing, etc.). This flexibility may change when DEA issues new permanent rules.

Do PMHNPs have the same prescribing authority as psychiatrists?

It depends on the state. In full-practice states (New York for experienced NPs, Illinois with FPA, California by 2026), PMHNPs can prescribe independently, including controlled substances for anxiety. In restricted states (Texas, Florida, Pennsylvania), PMHNPs need physician collaboration agreements and may face additional limits (e.g., Texas APRNs can’t prescribe Schedule II in outpatient settings).

What happens if I prescribe to a patient in a state where I’m not licensed?

You’re practicing medicine without a license, which is illegal and can result in serious consequences: license suspension or revocation in your home state, fines, inability to practice via telehealth platforms, and potential criminal charges. Always verify you hold an active license in the state where your patient is physically located during the visit.

How often do I need to check the state PDMP?

It varies by state. New York requires checking before every Schedule II–IV prescription. Pennsylvania requires it before each benzodiazepine or opioid prescription. Florida requires it before the first prescription and every 90 days thereafter. California requires checking at least every 4 months for ongoing controlled prescriptions. Check your state’s specific requirements and integrate PDMP queries into your workflow for every controlled prescription.

Can I conduct anxiety evaluations via phone instead of video?

For new patients and controlled substance prescribing, video is strongly recommended and often required. Federal DEA rules currently require audiovisual communication for new controlled prescriptions (under the temporary rules). Some states (like Illinois) explicitly allow audio-only for mental health when video isn’t available, but this creates compliance complexity with federal rules. Use video whenever possible for initial evaluations and any controlled substance prescribing.

What’s the difference between treating anxiety patients in California vs. Texas as a PMHNP?

In California (by 2026), you can practice independently with full prescribing authority after meeting experience requirements. In Texas, you must have a Prescriptive Authority Agreement with a physician, and you cannot prescribe Schedule II controlled substances in outpatient settings (limiting your ability to treat comorbid ADHD). You’d also need to ensure your collaborating physician approves benzodiazepine prescribing in your agreement. The regulatory burden is much higher in Texas.

How do I stay current on changing DEA telehealth rules?

Subscribe to DEA email updates (dea.gov), join professional associations (American Psychiatric Association for psychiatrists, American Association of Nurse Practitioners for PMHNPs), follow healthcare policy news sources like Axios or STAT News, and consider joining a telehealth platform that monitors regulatory changes and updates provider policies accordingly.

Citations

1. DEA and HHS. (2024, November 15). DEA and HHS Extend Telemedicine Flexibilities through 2025. [Press Release]. https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025

2. Center for Connected Health Policy. (2026, January 9). State Telehealth Policies for Online Prescribing. https://www.cchpca.org/topic/online-prescribing/

3. Florida Legislature. (2025). Florida Statute 456.47 – Telehealth Services. http://www.flsenate.gov/Laws/Statutes/2025/456.47

4. Texas Board of Nursing. (2025, December 9). APRN Prescriptive Authority FAQ – Schedule II Prescribing. https://www.bon.texas.gov/faqpracticeaprn.asp.html

5. New York State Department of Health. (2013). I-STOP Prescription Monitoring Program Requirements. https://health.ny.gov/professionals/narcotic/prescription_monitoring

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94